Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma

To understand how genomic heterogeneity of glioblastoma (GBM) contributes to the poor response to therapy, which is characteristic of this disease, we performed DNA and RNA sequencing on GBM tumor samples and the neurospheres and orthotopic xenograft models derived from them. We used the resulting data set to show that somatic driver alterations including single nucleotide variants, focal DNA alterations, and oncogene amplification in extrachromosomal DNA (ecDNA) elements were in majority propagated from tumor to model systems. In several instances, ecDNAs and chromosomal alterations demonstrated divergent inheritance patterns and clonal selection dynamics during cell culture and xenografting. Longitudinal patient tumor profiling showed that oncogenic ecDNAs are frequently retained after disease recurrence. Our analysis shows that extrachromosomal elements increase the genomic heterogeneity during tumor evolution of glioblastoma, independent of chromosomal DNA alterations.

[1]  Jessica M. Rusert,et al.  Extrachromosomal oncogene amplification drives tumor evolution and genetic heterogeneity , 2017, Nature.

[2]  L. Lamb,et al.  Receptor tyrosine kinase Met promotes cell survival via kinase-independent maintenance of integrin α3β1 , 2016, Molecular biology of the cell.

[3]  Steven J. M. Jones,et al.  Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.

[4]  Adam D. Thomas,et al.  DNA damage and the balance between survival and death in cancer biology , 2015, Nature Reviews Cancer.

[5]  Hanlee P. Ji,et al.  Pan-cancer analysis of the extent and consequences of intratumor heterogeneity , 2015, Nature Medicine.

[6]  B. Johansson,et al.  The emerging complexity of gene fusions in cancer , 2015, Nature Reviews Cancer.

[7]  Michael P. Schroeder,et al.  In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. , 2015, Cancer cell.

[8]  Jill S Barnholtz-Sloan,et al.  Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution , 2015, Genome research.

[9]  Sohrab P. Shah,et al.  Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution , 2014, Nature.

[10]  D. Bang,et al.  Novel fusion transcripts in human gastric cancer revealed by transcriptome analysis , 2014, Oncogene.

[11]  S. Antonarakis,et al.  Extrachromosomal driver mutations in glioblastoma and low grade glioma , 2014, Nature Communications.

[12]  R. Verhaak,et al.  The landscape and therapeutic relevance of cancer-associated transcript fusions , 2014, Oncogene.

[13]  G. Evan,et al.  Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis , 2014, Nature Communications.

[14]  J. Akers,et al.  RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas , 2014, Genome research.

[15]  Franziska Michor,et al.  Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma. , 2014, Cancer cell.

[16]  John N. Weinstein,et al.  PRADA: pipeline for RNA sequencing data analysis , 2014, Bioinform..

[17]  A. Bouchard-Côté,et al.  PyClone: statistical inference of clonal population structure in cancer , 2014, Nature Methods.

[18]  S. Nelson,et al.  Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA , 2014, Science.

[19]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[20]  David Haussler,et al.  Double minute chromosomes in glioblastoma multiforme are revealed by precise reconstruction of oncogenic amplicons. , 2013, Cancer research.

[21]  Ken Chen,et al.  A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. , 2013, Genes & development.

[22]  Carlos Caldas,et al.  The implications of clonal genome evolution for cancer medicine. , 2013, The New England journal of medicine.

[23]  V. P. Collins,et al.  Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics , 2013, Proceedings of the National Academy of Sciences.

[24]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[25]  D. Brat,et al.  Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma , 2012, Science.

[26]  Ryan M. Layer,et al.  Extrachromosomal MicroDNAs and Chromosomal Microdeletions in Normal Tissues , 2012, Science.

[27]  Charles Swanton,et al.  Intratumor Heterogeneity: Seeing the Wood for the Trees , 2012, Science Translational Medicine.

[28]  Debyani Chakravarty,et al.  Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response , 2012, Proceedings of the National Academy of Sciences.

[29]  Stephen Yip,et al.  Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. , 2012, Neuro-oncology.

[30]  Jeffrey W. Clark,et al.  Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Rebecca A Betensky,et al.  Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. , 2011, Cancer cell.

[32]  Ming-Sound Tsao,et al.  An overview of the c-MET signaling pathway , 2011, Therapeutic advances in medical oncology.

[33]  Qian Wang,et al.  A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3 , 2011, Clinical Cancer Research.

[34]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[35]  Domenico Trombetta,et al.  Gene amplification as double minutes or homogeneously staining regions in solid tumors: origin and structure. , 2010, Genome research.

[36]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[37]  Hui Wang,et al.  c-Myc Is Required for Maintenance of Glioma Cancer Stem Cells , 2008, PloS one.

[38]  D. Gisselsson,et al.  Binomial Mitotic Segregation of MYCN-Carrying Double Minutes in Neuroblastoma Illustrates the Role of Randomness in Oncogene Amplification , 2008, PloS one.

[39]  A. Bardelli,et al.  Genetic targeting of the kinase activity of the Met receptor in cancer cells , 2007, Proceedings of the National Academy of Sciences.

[40]  A. Ferrando,et al.  Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia , 2004, Nature Genetics.

[41]  F. Apiou,et al.  Molecular structure of double-minute chromosomes bearing amplified copies of the epidermal growth factor receptor gene in gliomas. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[42]  L. Tsui,et al.  Identification of an amplified gene cluster in glioma including two novel amplified genes isolated by exon trapping , 1997, Human Genetics.

[43]  F. Alt,et al.  Transposition and amplification of oncogene-related sequences in human neuroblastomas , 1983, Cell.

[44]  A. I. Spriggs,et al.  MINUTE CHROMATIN BODIES IN MALIGNANT TUMOURS OF CHILDHOOD. , 1965, Lancet.

[45]  Todd.  KING'S COLLEGE HOSPITAL.: Adipose Deposit in the Muscular Fibrillœ of the Heart ; Inefficient Action of the Organ; Anasarca and Ascites; Death; Autopsy , 1853 .